Literature DB >> 23331030

CFTR inhibitors.

Alan S Verkman1, David Synder, Lukmanee Tradtrantip, Jay R Thiagarajah, Marc O Anderson.   

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated Cl- channel whose major function is to facilitate epithelial fluid secretion. Loss-of-function mutations in CFTR cause the genetic disease cystic fibrosis. CFTR is required for transepithelial fluid transport in certain secretory diarrheas, such as cholera, and for cyst expansion in autosomal dominant polycystic kidney disease. High-throughput screening has yielded CFTR inhibitors of the thiazolidinone, glycine hydrazide and quinoxalinedione chemical classes. The glycine hydrazides target the extracellular CFTR pore, whereas the thiazolidinones and quinoxalinediones act at the cytoplasmic surface. These inhibitors have been widely used in cystic fibrosis research to study CFTR function at the cell and organ levels. The most potent CFTR inhibitor has IC50 of approximately 4 nM. Studies in animal models support the development of CFTR inhibitors for antisecretory therapy of enterotoxin-mediated diarrheas and polycystic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23331030      PMCID: PMC4012685          DOI: 10.2174/13816128113199990321

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  77 in total

Review 1.  Chloride channels as drug targets.

Authors:  Alan S Verkman; Luis J V Galietta
Journal:  Nat Rev Drug Discov       Date:  2008-01-19       Impact factor: 84.694

2.  Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model.

Authors:  Lukmanee Tradtrantip; N D Sonawane; Wan Namkung; A S Verkman
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

Review 3.  Treatment strategies and clinical trial design in ADPKD.

Authors:  Vicente E Torres
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

Review 4.  Novel targets for the treatment of autosomal dominant polycystic kidney disease.

Authors:  Franck A Belibi; Charles L Edelstein
Journal:  Expert Opin Investig Drugs       Date:  2010-03       Impact factor: 6.206

Review 5.  Ion transport in the small intestine.

Authors:  Jayashree Venkatasubramanian; Mei Ao; Mrinalini C Rao
Journal:  Curr Opin Gastroenterol       Date:  2010-03       Impact factor: 3.287

6.  Molecular models of the open and closed states of the whole human CFTR protein.

Authors:  Jean-Paul Mornon; Pierre Lehn; Isabelle Callebaut
Journal:  Cell Mol Life Sci       Date:  2009-08-26       Impact factor: 9.261

Review 7.  The role of the mammalian target of rapamycin (mTOR) in renal disease.

Authors:  Wilfred Lieberthal; Jerrold S Levine
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

Review 8.  Advances in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Vishal Patel; Renuka Chowdhury; Peter Igarashi
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-03       Impact factor: 2.894

9.  Architecture of the cystic fibrosis transmembrane conductance regulator protein and structural changes associated with phosphorylation and nucleotide binding.

Authors:  Liang Zhang; Luba A Aleksandrov; Zhefeng Zhao; James R Birtley; John R Riordan; Robert C Ford
Journal:  J Struct Biol       Date:  2009-06-12       Impact factor: 2.867

10.  Epac1 mediates protein kinase A-independent mechanism of forskolin-activated intestinal chloride secretion.

Authors:  Kazi Mirajul Hoque; Owen M Woodward; Damian B van Rossum; Nicholas C Zachos; Linxi Chen; George P H Leung; William B Guggino; Sandra E Guggino; Chung-Ming Tse
Journal:  J Gen Physiol       Date:  2010-01       Impact factor: 4.086

View more
  16 in total

1.  Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.

Authors:  Onur Cil; Puay-Wah Phuan; Anne Marie Gillespie; Sujin Lee; Lukmanee Tradtrantip; Jianyi Yin; Ming Tse; Nicholas C Zachos; Ruxian Lin; Mark Donowitz; Alan S Verkman
Journal:  FASEB J       Date:  2016-11-08       Impact factor: 5.191

2.  Functional evaluation of the cystic fibrosis transmembrane conductance regulator in the endocervix†.

Authors:  Leo Han; Mackenzie Roberts; Addie Luo; Shuhao Wei; Ov D Slayden; Kelvin D Macdonald
Journal:  Biol Reprod       Date:  2022-09-12       Impact factor: 4.161

3.  Loss of MYO5B Leads to Reductions in Na+ Absorption With Maintenance of CFTR-Dependent Cl- Secretion in Enterocytes.

Authors:  Amy C Engevik; Izumi Kaji; Melinda A Engevik; Anne R Meyer; Victoria G Weis; Anna Goldstein; Michael W Hess; Thomas Müller; Hermann Koepsell; Pradeep K Dudeja; Matthew Tyska; Lukas A Huber; Mitchell D Shub; Nadia Ameen; James R Goldenring
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

4.  Bioactivity-guided fractionation of an antidiarrheal Chinese herb Rhodiola kirilowii (Regel) Maxim reveals (-)-epicatechin-3-gallate and (-)-epigallocatechin-3-gallate as inhibitors of cystic fibrosis transmembrane conductance regulator.

Authors:  Lei Chen; Bo Yu; Yaofang Zhang; Xin Gao; Liang Zhu; Tonghui Ma; Hong Yang
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

5.  Identification of resveratrol oligomers as inhibitors of cystic fibrosis transmembrane conductance regulator by high-throughput screening of natural products from chinese medicinal plants.

Authors:  Yaofang Zhang; Bo Yu; Yujie Sui; Xin Gao; Hong Yang; Tonghui Ma
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

Review 6.  The Role of Ion Transporters in the Pathophysiology of Infectious Diarrhea.

Authors:  Soumita Das; Rashini Jayaratne; Kim E Barrett
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-03-05

7.  Substratum stiffness tunes membrane voltage in mammary epithelial cells.

Authors:  Brian B Silver; Sherry X Zhang; Emann M Rabie; Celeste M Nelson
Journal:  J Cell Sci       Date:  2021-07-12       Impact factor: 5.235

8.  Iron Homeostasis and Inflammatory Status in Mice Deficient for the Cystic Fibrosis Transmembrane Regulator.

Authors:  Jean-Christophe Deschemin; Sarah Allouche; Franck Brouillard; Sophie Vaulont
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

9.  Antiestrogen- and tamoxifen-induced effects on calcium-activated chloride currents in epithelial cells carrying the ∆F508-CFTR point mutation.

Authors:  Roberto Imberti; Maria Lisa Garavaglia; Ivan Verduci; Gaetano Cannavale; Giorgio Balduzzi; Sara Papetti; Michele Mazzanti
Journal:  Respir Res       Date:  2018-10-05

Review 10.  Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas.

Authors:  Hugo R de Jonge; Maria C Ardelean; Marcel J C Bijvelds; Paola Vergani
Journal:  FEBS Lett       Date:  2020-11-16       Impact factor: 3.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.